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INTRODUCTION 
 The most common cardiac arrhythmia is Atrial Fibrillation (AF) 
(estimated lifetime risk , 22-26%). Approximately, it accounts for 33% of 
arrhythmia related hospitalization. It is a supraventricular tachyarrhythmia 
characterized by uncoordinated atrial activation leading to deterioration of 
mechanical function of the atria. Recognition of this disorder is important 
because it is associated with significant morbidity and mortality.  
 Atrial fibrillation has substantial consequences in population health, 
including impaired quality of life, increased hospitalization rates, stroke 
occurrence and increased medical costs. Atrial fibrillation is associated with an 
increase in the risk of stroke by fivefold and the risk of all-cause mortality by 
twofold.[1] It is also associated with the development of heart failure and has been 
linked to sudden death. 
 The incidence of atrial fibrillation is age and gender related ,ranging from  
0.1%per year before the age of 40 to more than 1.5% per year in women and 
more than 2% per year in men older than 80 years. 
 Rarely a primary electric disorder, Atrial Fibrillation commonly 
represents the final common pathway for a multitude of other predisposing 
cardiac and non-cardiac conditions. The independent risk factors for the 
development of atrial fibrillation are congestive heart failure, aortic and mitral 
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valve disease, left atrial enlargement, hypertension, advanced age, obesity and 
obstructive sleep apnea.[2] 
 Atrial fibrillation is the most common arrhythmia that requires treatment 
as it is frequently encountered in clinical practice. Although the majority of 
patients with atrial fibrillation are relatively asymptomatic, patients can have 
profoundly limiting symptoms due to rapid or slow basal ventricular rates, a 
rapid cardio accelerator response to exercise, beat to beat irregularity with 
associated palpitations, and the loss of atrial systolic contribution to ventricular 
filling lead to diminished cardiac output. 
 Better recognition of clinical epidemiology of AF, along with an 
improved appreciation of the underlying mechanisms, is essential for 
development in improved methods for AF prevention and management. 
 This study was undertaken to analyse the clinical and echocardiographic 
profile of patients coming with Atrial fibrillation at Institute of Internal 
Medicine, Madras Medical College, Chennai. 
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AIMS AND OBJECTIVES 
 To analyse the etiological factors, clinical presentation, 
echocardiographic features and complications of 100 cases of atrial 
fibrillation in Rajiv Gandhi Government General Hospital, Chennai- 3. 
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REVIEW OF LITERATURE 
 Atrial fibrillation (AF) is characterized by disorganized, rapid, irregular 
atrial activation with loss of atrial contraction and with an irregular ventricular 
rate that is determined by AV nodal conduction. When untreated, the ventricular 
rate also tends to be rapid and variable, between 120 and 160 beats/min , in some 
patients the rate may exceed 200beats /min. Those with slower rate are due to 
high vagal tone and AV nodal conduction disease.[3] 
EPIDEMIOLOGY OF ATRIAL FIBRILLATION: 
 Atrial fibrillation is the most common sustained arrhythmia and is a major 
public health problem. The incidence of atrial fibrillation is age and gender 
related ,ranging from  0.1%per year before the age of 40 to more than 1.5% per 
year in women and more than 2% per year in men older than 80 years. The 
prevalence is increased with age, and more than 95% of AF patients are more 
than 60 years of age. The prevalence is approximately 10% by the age of 80. 
Atrial fibrillation is slightly more common in men than in women, and more 
common in whites than blacks.[2] 
Apart from age, prevalence of AF is greater in patients with conditions 
such as hypertension, heart failure, coronary artery disease (CAD), valvular heart 
disease, obesity, diabetes mellitus or chronic kidney disease. The increase in 
prevalence is attributed to better detection of silent AF as well as increasing age 
and conditions predisposing to AF. 
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HEALTH CARE BURDEN, MORBIDITY AND MORTALITY OF 
ATRIAL FIBRILLATION: 
 AF is associated with an all-cause mortality that is increased by two-fold 
in women and by 1.5fold in men. Anticoagulation has largely mitigated the 
deaths due to stroke ,whereas cardiovascular deaths , due to heart failure and 
sudden death is still common even when treated according to the current 
recommendations. It is also associated with an increased morbidity such as heart 
failure and stroke.  
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TABLE-1: CARDIOVASCULAR MORBIDITY AND MORTALITY 
ASSOCIATED WITH ATRIAL FIBRILLATION:[4] 
 
CLASSIFICATION OF ATRIAL FIBRILLATION: [4] 
 AF is classified into five types based on the presentation, duration and 
spontaneous termination of episodes. 
First Diagnosed AF: 
AF that has not been diagnosed before, irrespective of the duration of the 
arrhythmia or the presence and severity of AF-related symptoms. 
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Paroxysmal AF: 
It is self-terminating, in most cases within 48 hours. Some AF paroxysms 
may continue for up to 7 days.AF episodes that are treated by cardioversion 
within 7 days should also be considered paroxysmal. 
Persistent AF: 
 AF that lasts longer than 7 days, including episodes that are terminated 
by cardioversion, either with drugs or by direct current cardio version, after  
7 days or more. 
Long-standing persistent AF: 
Continuous AF lasting for ≥1 year, when it is decided to adopt a rhythm 
control strategy. 
Permanent AF: 
AF that is accepted by the patient (and physician). Hence, rhythm control 
interventions are, by definition, not pursued in patients with permanent AF. 
Should a rhythm control strategy be adopted, the arrhythmia would be re-
classified as ‘long-standing persistent AF’. 
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MECHANISMS OF ATRIAL FIBRILLATION: 
The mechanisms responsible for AF are quite complex. Triggering events 
may be different from the ones responsible for maintenance mechanisms.  
Additionally, the clinical phenotypes of paroxysmal, persistent, and 
longstanding persistent have differing electrophysiologic characteristics due to 
remodelling and different clinical modulators, like heart failure, atrial stretch and 
ischemia, sympathovagal influences, inflammation, and fibrosis. 
The two likely electrophysiologic mechanisms of AF are : 
 one or more automatic, triggered, or micro reentrant foci, so-called 
drivers, which fire at rapid rates and cause fibrillation-like activity, and 
 multiple reentrant circuits meandering throughout the atria, annihilating 
and reforming wavelets that perpetuate the fibrillation.  
In many studies the left atrium contains the site of dominant frequency 
discharge, with a left-to-right gradient. Both mechanisms may be present 
simultaneously and can change as the atria remodel. 
 In the CONFIRM trial, computational maps were obtained in patients by 
signal processing of multiple electrograms recorded simultaneously during AF. 
This technique can reveal rotors and focal sources. A mean of 2.1 sources was 
found in 97% of 101 patients, with 70% being rotors and 30% being focal 
sources.[5] 
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 Rapid discharges from the pulmonary veins are the most common triggers 
of AF and also may play a perpetuating role, more so in paroxysmal AF than in 
persistent AF. This is why pulmonary vein isolation is particularly effective for 
elimination of paroxysmal AF. In persistent AF, changes in the atrial substrate, 
including interstitial fibrosis that contributes to slow, discontinuous, and 
anisotropic conduction, may give rise to complex fractionated atrial electrograms 
(CFAEs) and reentry. Therefore, pulmonary vein isolation alone often is 
insufficient to eliminate persistent AF.[5] 
FIGURE 1: CLINICAL TYPES OF AF AND THE PATHOLOGICAL 
CHANGES 
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GENETIC FACTORS: 
AF, especially early-onset AF, has a strong heritable component and it is 
independent of concomitant cardiovascular conditions. A few AF patients who 
are  young suffer from inherited cardiomyopathies or channelopathies mediated 
by disease-causing mutations. These monogenic diseases also convey a risk for 
sudden death.  
Up to one-third of AF patients carry common genetic variants that 
predispose to AF, with a relatively low added risk. At least14 of these variants, 
often single nucleotide polymorphisms, are known to increase the risk of 
prevalent AF in populations. The most important variants are those that are 
located close to the paired-like homeodomain transcription factor 2 (Pitx2) 
gene on chromosome 4q25.These variants modify the risk of AF upto seven-
fold.[6,7] 
Several mutations that are responsible for familial AF and that which 
predispose to AF have been identified. These mutations cause a gain of function 
of repolarization potassium currents which results in shortening of atrial 
refractoriness and facilitation of atrial re-entry. Multiple polymorphisms 
associated with idiopathic AF or structural heart disease or occurring 
postoperatively also have been identified in genes which affect potassium and 
sodium channels, the renin-angiotensin system, connexin-40, endothelial nitric 
oxide synthase, and interleukin-10. The end results are changes in calcium 
handling, fibrosis, conduction, and inflammation that predispose to AF.[8] 
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In the future genetic variants could, become useful for patient selection of 
rhythm or rate control. While genomic analysis may provide an opportunity to 
improve the diagnosis and management of AF in the future, routine genetic 
testing for common gene variants associated with AF need not be recommended 
at present. 
ETIOLOGY OF ATRIAL FIBRILLATION: 
CARDIOVASCULAR DISEASES: 
1. Rheumatic heart disease 
2. Coronary artery disease 
3. Systemic Hypertension 
4. Congenital heart disease 
a. Atrial septal Defect 
b. Lutembacher syndrome 
c. Tricuspid Artesia 
d. Ebsteins anomaly 
5. Cardiomyopathy 
a. Dilated 
b. Hypertrophic 
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6. Sick Sinus syndrome 
7. Diffuse myocardial disease – myocarditis 
8. Pericardial disease 
a. Constrictive pericarditis 
b. Pericardial effusion 
9. Pre – Excitation syndromes 
a. Wolff Parkinson White syndrome 
b. Lown Ganong Levine syndrome 
10. Syphilitic heart disease 
11. Bacterial Endocarditis 
12. Atrial myxoma 
13. Metabolic 
a. Hyperthyroidism 
b. Hyperkalemia 
c. Uremia 
14. Following open heart or thoracic surgery 
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NEUROLOGIC DISEASE 
Meningitis 
Emotional Stress 
MISCELLANEOUS CAUSES 
During Anesthesia 
Obstructive sleep apnea 
Drugs & chemicals 
a) Alcohol 
b) Smoking 
c) Coffee 
d) Digitalis 
e) Adrenaline 
Vomiting spells 
Lone Atrial Fibrillation 
CHRONIC DISEASE ASSOCIATIONS  
In developed countries. Hypertensive heart disease and coronary heart 
disease (CHD) are the most common underlying chronic disorders in patients 
with atrial fibrillation . Rheumatic heart disease, though now uncommon in 
14 
 
developed countries, is associated with a much higher incidence of AF and still 
remains the commonest cause in developing countries. 
Hypertensive heart disease — In a longitudinal study of male air crew 
recruits, a history of hypertension was shown to increase the risk of developing 
AF 1.42-fold. Although this is a relatively small increase in risk, the high 
frequency of hypertension in the general population results in hypertensive heart 
disease being the most common underlying disorder in patients with AF, apart 
from rheumatic etiology.[9,10] 
Coronary disease — AF is uncommonly associated with CHD unless it 
is complicated by acute myocardial infarction (MI) or heart failure (HF). AF is 
found to occur transiently in 6 to 10 percent of patients with an acute MI, 
presumably due to atrial ischemia or atrial stretching secondary to HF  
The incidence of AF is much lower in patients with chronic stable CHD. 
In the Coronary Artery Surgical Study (CASS), which included over 18,000 
patients with angiographically documented coronary artery disease, AF was 
present in only 0.6 percent. AF was associated with age greater than 60, male 
sex, mitral regurgitation (MR), and HF; there was no association between AF 
and the number of coronary arteries involved.[11,12] 
Valvular heart disease — Any valvular lesion that leads to significant 
stenosis or regurgitation is associated with the development of AF. The 
following are representative frequencies: 
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● In a review of 89 patients with mitral valve prolapse (and grade 3 or 4 MR) 
and 360 with flail leaflets, the rate of development of AF was about 5 
percent per year with both types of lesions . The major independent risk 
factors were age ≥65 years and baseline left atrial dimension ≥50 mm. 
● Rheumatic heart disease is associated with a high prevalence of AF In a 
study of approximately 1100 patients with rheumatic heart disease, the 
prevalence varied with the type of valve disease [13] 
•Mitral stenosis (MS), MR, and tricuspid regurgitation – 70 % 
•Isolated MS – 29 % 
•Isolated MR – 16 % 
Heart failure — AF and HF often occur together, and each may 
predispose to the other [14]. Among patients with HF, the prevalence of AF is 
variable, depending in part upon the severity of HF. 
Hypertrophic cardiomyopathy — AF has been reported in 10 to 28 
percent of patients with hypertrophic cardiomyopathy [15]. 
Congenital heart disease — AF has been reported in approximately 20 
percent of adults with an atrial septal defect  However, the incidence of AF is 
related to age, ranging in one series from 15 percent for those aged 40 to 60, to 
61 percent for those over the age of 60 [16]. 
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AF and/or atrial flutter also occurs in other forms of congenital heart 
disease that affect the atria, including Ebstein anomaly and patent ductus 
arteriosus, and after surgical correction of some other abnormalities, including 
ventricular septal defect, tetralogy of Fallot, pulmonic stenosis, and transposition 
of the great vessels. 
Venous thromboembolic disease — Venous thromboembolic disease, 
which includes deep vein thrombosis and pulmonary embolism, is associated 
with an increased risk of AF. The mechanism is not known but has been 
speculated to be related to the increase in pulmonary vascular resistance and 
cardiac afterload, which may lead to right atrial strain [17]. 
The incidence of AF in patients with acute or chronic venous 
thromboembolic disease has not been well studied. It has been reported to be in 
the 10 to 14 percent range in patients with documented pulmonary embolism  
Other types of cardiopulmonary disease — AF is associated with a 
variety of other types of cardiopulmonary disease: 
●AF also occurs in chronic obstructive pulmonary disease, peripartum 
cardiomyopathy, lupus myocarditis, and both idiopathic and uremic 
pericarditis . 
●There is a possible causal relationship between obstructive sleep apnea 
(OSA) and AF. In a series of 39 patients diagnosed with both PAF and OSA, 
patients receiving treatment with continuous positive pressure ventilation 
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had a lower incidence of AF recurrence at 12 months (42 versus 82 percent 
for patients who were not treated) [18]. 
Obesity — Obese individuals (body mass index [BMI] >30 kg/m2) are 
significantly more likely to develop AF than those with a normal BMI 
(<25 kg/m2) [19]. In the Framingham Heart Study, every unit increase in BMI was 
associated with an approximate 5 percent increase in risk [20]. 
Diabetes — In a study of over 4700 individuals without valvular heart 
disease in the Framingham Heart Study, the presence of diabetes was associated 
with a significantly increased risk for the development of AF in multivariate 
analysis (odds ratio 1.1 for men and 1.5 for women)  Increased left ventricular 
mass and increased arterial stiffness have been put forth as possible mechanisms 
[21]. 
Metabolic syndrome — As discussed above, the presence of hypertension, 
diabetes, or obesity is associated with an increased likelihood of the development 
of AF. The metabolic syndrome includes these three, as well as dyslipidemia 
POTENTIALLY REVERSIBLE TRIGGERS 
In the Framingham Heart Study, 1409 individuals with new onset AF 
were evaluated for their risk of subsequent occurrences based on whether they 
had a secondary precipitant or not [23]. A precipitant was found in 439 (31 
percent) and included cardiothoracic surgery (30 percent), infection (23 percent), 
non-cardiothoracic surgery (20 percent), and acute myocardial infarction (18 
percent). Other secondary precipitants included acute alcohol consumption, 
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thyrotoxicosis, acute pericardial disease, acute pulmonary embolism, and other 
acute pulmonary pathology.  
Surgery — AF occurs in relation to a variety of different types of surgery, with 
the incidence greatest in patients undergoing cardiac surgery: 
●Cardiac surgery – AF has been reported in up to 30 to 40 percent of 
patients in the early postoperative period following coronary artery bypass 
graft surgery (CABG) , in 37 to 50 percent after valve surgery , and in as 
many as 60 percent undergoing valve replacement plus CABG [25,26]. 
●Cardiac transplantation – AF has been described in 10 to 24 percent of 
patients with a denervated transplanted heart, often in the absence of 
significant rejection Most episodes occur within the first two weeks, while 
AF developing after two weeks may be associated with an increased risk of 
subsequent death [27,28] 
●Noncardiac surgery – AF is less common after noncardiac compared 
with cardiac surgery. The reported incidence of new onset AF in patients 
undergoing noncardiac surgery ranges from 1 and 40 percent. This broad 
range is likely due to variability in patient and surgical characteristics [29,30]. 
Hyperthyroidism — Patients with hyperthyroidism have an increased risk 
of developing AF. In one population-based study of 40,628 patients with clinical 
hyperthyroidism, 8.3 percent had AF or atrial flutter [31]. AF occurred in 10 to 20 
percent of patients over age 60 but in less than 1 percent of patients under age 
40. Men were more likely to have AF than women (12.1 versus 7.6 percent).  
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Increased beta adrenergic tone may be in part responsible for the 
development of AF in hyperthyroidism and may also contribute to the rapid 
ventricular response in this setting. The mechanism is unknown, but may be 
related to an increased automaticity and enhanced triggered activity of 
pulmonary vein cardiomyocytes, which can be a source of ectopic beats that 
initiate AF. 
The risk of AF is also increased in patients with subclinical 
hyperthyroidism (defined as a low serum thyroid stimulating hormone 
concentration and normal serum thyroid hormone concentrations).The increase 
in risk is illustrated by the following observations: 
●In a prospective study, 2007 subjects ≥60 years of age who did not have 
AF were followed for 10 years .The subsequent age-adjusted incidence of 
AF was significantly higher among those with a low serum thyroid 
stimulating hormone concentration compared with those with a normal 
value (28 versus 10 per 1000 person-years). 
●In a review of 23,638 subjects, the prevalence of AF in those with clinical 
and subclinical hyperthyroidism was similar (14 and 13 percent, 
respectively) and higher than that in euthyroid subjects (2.3 percent) [31]. 
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EVALUATION — The history, physical examination, and specific laboratory 
and cardiologic testing are all part of the evaluation of the patient with atrial 
fibrillation (AF). 
History and physical examination — Not all patients with AF are 
symptomatic. Among those that are, symptoms associated with AF are variable 
and the history should focus on obtaining the following information: 
●A description of the symptoms: onset or date of discovery, the frequency 
and duration, severity, and qualitative characteristics. 
Typical symptoms include palpitations, tachycardia, fatigue, 
weakness, dizziness, lightheadedness, reduced exercise capacity, increased 
urination, or mild dyspnea. More severe symptoms include dyspnea at rest, 
angina, presyncope, or infrequently, syncope. In addition, some patients 
present with an embolic event or the insidious onset of heart failure (as 
manifested by pulmonary edema, peripheral edema, weight gain, and 
ascites). 
A semi-quantitative method to classify symptoms has been developed. 
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Table 2 : Modified European Heart Rhythm Association symptom scale 
(modified from Wynn et al) [32] 
 
●Precipitating causes: exercise, emotion, or alcohol. 
●The presence of the following disease associations: cardiovascular or 
cerebrovascular disease, diabetes, hypertension, chronic obstructive 
pulmonary disease, obstructive sleep apnea, or potentially reversible causes 
(eg, hyperthyroidism, excessive alcohol ingestion).  
●A complete examination of the cardiovascular system should be performed 
in all individuals with newly diagnosed AF and in those with a change in 
symptom status. Abnormal findings may inform healthcare providers about 
either contributing factors for (eg, murmur of mitral stenosis) or the impact 
of (eg, evidence of heart failure) AF. 
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Electrocardiogram — The electrocardiogram (ECG) is used to verify the 
presence of AF and is necessary to make the diagnosis. AF has the following 
electrocardiographic characteristics  
●The RR intervals follow no repetitive pattern. They have been labelled as 
“irregularly irregular.” 
●While electrical activity suggestive of P waves may be seen in some leads, 
there are no distinct P waves. Thus, even when an atrial cycle length (the 
interval between two atrial activations or the P-P interval) can be defined, it 
is not regular and often less than 200 milliseconds (translating to an atrial 
rate greater than 300 beats per minute). 
●Markers of nonelectrical cardiac disease, such as left ventricular 
hypertrophy (possible hypertension) or Q waves (possible coronary artery 
disease). 
●Markers of electrical heart disease, including the presence of ventricular 
pre-excitation or infranodal conduction disease (bundle branch block). 
●The QT interval (to identify the potential risk of antiarrhythmic therapy) 
●Evidence of severe bradycardia or sinus node dysfunction 
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FIGURE 2 : ECG OF A PATIENT WITH ATRIAL FIBRILLATION 
Echocardiogram — The transthoracic echocardiogram (TTE) is performed to 
evaluate the size of the right and left atria and the size and function of the right 
and left ventricles; to detect possible valvular heart disease, left ventricular 
hypertrophy, and pericardial disease; and to assess peak right ventricular 
pressure. 
The TTE may also identify left atrial thrombus, although the sensitivity is low. 
Transesophageal echocardiography is much more sensitive for identifying 
thrombi in the left atrium or left atrial appendage and can be used to determine 
the need for anticoagulation prior to any attempt at pharmacologic or electrical 
cardioversion. 
Additional cardiac testing — Exercise testing is reasonable for patients with 
signs or symptoms of ischemic heart disease. It is also useful to help guide 
pharmacotherapy for AF, as some antiarrhythmic medications are 
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contraindicated in patients with coronary artery disease. In addition, stress 
testing may be helpful in gauging adequacy of heart rate control in AF during 
exercise. Insufficient heart rate control in AF is a major factor for exercise 
intolerance in AF.  
Ambulatory cardiac monitoring with event recorders, adhesive extended 
time event monitors, or implantable loop monitors can be used to identify the 
arrhythmia if it is intermittent and not captured on routine electrocardiography. 
Ambulatory ECG monitoring can also be utilized to correlate symptoms to the 
arrhythmia along with assessment of the AF burden. Twenty-four- to 48-hour 
Holter monitoring mainly aids in the evaluation of overall ventricular response 
rates in individuals where a rate control strategy has been chosen and there is 
concern for inadequate heart rate control or bradycardia.  
Baseline laboratory testing — Clinical or subclinical hyperthyroidism is 
present in less than 5 percent of patients with AF [33].A thyroid-stimulating 
hormone (TSH) and free T4 levels should be obtained in all patients with a first 
episode of AF, or in those who develop an increase in AF frequency.  
Other important baseline tests include a complete blood count, a serum 
creatinine, an analysis for proteinuria, and a test for diabetes mellitus  
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MANAGEMENT OF ATRIAL FIBRILLATION: 
 
FIGURE 3 – INTEGRATED MANAGEMENT OF ATRIAL 
FIBRILLATION[3] 
 
FIGURE 4– MANAGEMENT OF PATIENTS PRESENTING 
ACUTELY WITH AF AND HEART FAILURE [4] 
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STROKE PREVENTION THERAPY IN PATIENTS WITH ATRIAL 
FIBRILLATION: 
The majority of patients warrant chronic anticoagulation, but selection of 
therapy should be individualized based on patient profile and risks and benefits 
of individual agents. Anticoagulation with a vitamin K antagonist is warranted 
for all patients with AF who have rheumatic mitral stenosis or mechanical heart 
valves for whom the newer anticoagulants have not been tested. Anticoagulation 
with a vitamin K antagonist (warfarin) or the newer oral anticoagulants is 
warranted for patients who have had more than 48 h of AF and are undergoing 
cardioversion, for patients who have a prior history 
of stroke, or for patients with a CHA2DS2-VASc score of ≥2, but it may be 
considered in patients with a risk score of 1. [2]  
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TABLE 3 : CLINICAL RISK FACTORS FOR STROKE, TRANSIENT 
ISCHAEMIC ATTACK, AND SYSTEMIC EMBOLISM IN THE 
CHA2DS2-VASC SCORE[35] 
 
 
The approach to patients with paroxysmal AF is the same as for persistent 
AF. It is recognized that many patients who appear to have infrequent AF 
episodes often have asymptomatic episodes that put them at risk. Absence of AF 
during periodic monitoring is not sufficient to indicate low risk.  
An important consideration in patients treated with an oral anticoagulants 
the risk of bleeding. Several risk-scoring systems have been developed to assess 
a patient’s susceptibility to hemorrhagic complications. The scoring system with 
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the best balance of simplicity and accuracy is the HAS-BLED score. The 
components of this score are hypertension, abnormal renal or liver function, 
stroke, bleeding history or predisposition, labile international normalized ratio 
(INR), elderly (>75 years), and concomitant drug (antiplatelet agent or 
nonsteroidal anti-inflammatory drug) or alcohol use. Each of these components 
is 1 point. As the score increases from 0 to the maximum of 9, there is a stepwise 
increase in the risk of bleeding in patients treated with warfarin. For example, in 
one study the annual rate of major bleeds was 1.1% in patients with a HAS-
BLED score of 0, 3.7%with a score of 3, and 12.5% with a score of 5.[35] 
TABLE 4: CLINICAL CHARACTERISTICS COMPRISING THE HAS-
BLED BLEEDING RISK SCORE 
 
Major bleeding requiring transfusion or in a critical area (e.g., 
intracranial) occurs in approximately 1% of patients per year. Risk factors for 
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bleeding include age >65–75 years, heart failure, history of anemia, and 
excessive alcohol or nonsteroidal anti-inflammatory drug use. Patients with 
coronary stents who require antiplatelet therapy with aspirin and a thienopyridine 
are at particularly high risk of bleeding. 
 Warfarin reduces the annual risk of stroke by 64% compared to placebo 
and by 37% compared to antiplatelet therapy. The newer anticoagulants, 
dabigatran, rivaroxaban, and apixaban, have been found to be non-inferior to 
warfarin in individual trials, and analysis of pooled data suggests superiority to 
warfarin by small absolute margins of 0.4–0.7% in reduction of mortality, stroke, 
major bleeding, and intracranial hemorrhage. Warfarin is an inconvenient agent 
that requires several days to achieve a therapeutic effect (prothrombin time 
[PT]/international normalized ratio [INR] >2), requires monitoring of PT/INR to 
adjust dose, and has many drug and food interactions, thus limiting patient 
compliance. Warfarin anticoagulation can be reversed by administration of fresh 
frozen plasma and vitamin K. [3] 
NOVEL ORAL ANTICOAGULANTS  
Direct thrombin inhibitors and factor Xa inhibitors have several 
advantages over vitamin K antagonists such as warfarin, the most notable being 
a fixed dosing regimen that eliminates the need for monitoring of a laboratory 
test such as the INR. Dabigatran, an oral direct thrombin inhibitor, and 
rivaroxaban and apixaban, factor Xa inhibitors, are approved by the U.S. Food 
and Drug Administration (FDA) for prevention of stroke/embolism in patients 
with nonvalvular AF. The NOACs, in addition to eliminating the need for 
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laboratory monitoring, have other advantages over warfarin: fewer drug 
interactions ,no food interactions, and rapid onset of action that obviates the need 
for bridging therapy. However, they also have some disadvantages Compared to 
warfarin: higher cost more gastrointestinal side effects in the case of dabigatran, 
twice-daily dosing for dabigatran and apixaban, and the absence of a readily 
available laboratory test to verify compliance. Furthermore, these agents cannot 
be used safely in patients with severe renal disease. Another limitation is that 
there are no specific reversal agents for all the NOACs. The FDA recently 
approved idarucizumab, an antibody fragment that reverses the anticoagulant 
effects of dabigatran within minutes. Prothrombin complex concentrate can 
reverse the anticoagulant effect of the NOACs, but specific and rapid-acting 
antidotes for rivaroxaban and apixaban are not yet available. Nonetheless, for 
many patients with AF, the advantages of the newer anticoagulants outweigh the 
disadvantages.[36,37] 
 
ANTI PLATELET AGENTS: 
The antiplatelet agents aspirin and clopidogrel are inferior to warfarin for 
stroke prevention in AF and do not reduce the risk of bleeding. Clopidogrel 
combined with aspirin is better than aspirin alone but inferior to warfarin and has 
greater bleeding risk than aspirin alone. Chronic anticoagulation is 
contraindicated in some patients due to bleeding risks. [3] 
 
 
31 
 
RATE CONTROL THERAPY IN PATIENTS WITH AF: 
ACUTE RATE CONTROL:  
Beta blockers and non dihyropyridine calcium channel blockers 
(verapamil,diltiazem) are preferred over digoxin due to their rapid onset of action 
and effectiveness in high sympathetic tone. In unstable patients, urgent 
cardioversion should be done.[38,39] 
LONG TERM PHARMACOLOGIC RATE CONTROL: 
The first line drugs used are beta blockers as monotherapy. Verapamil and 
diltiazem also provide reasonable control in patients with AF. But they should 
be avoided in patients with HFrEF due to their negative inotropic effects. 
Digoxin at lower doses(<250microgram once daily) may be associated with a 
better prognosis.[40]When medications fail to control ventricular rate, 
atrioventricular node/His bundle ablation  and implantation of a VVI pacemaker 
can control the ventricular rate. 
TARGET HEART RATE IN ATRIAL FIBRILLATION: 
The optimal heart rate target in AF patients is unclear. The RACE(Rate 
Control Efficacy in Permanent Atrial Fibrillation) II study randomized614 
patients with permanent AF to either a target heartrate ,80b.p.m. at rest and 110 
b.p.m. during moderate exercise, or to a lenient heart rate target of 110 b.p.m. 
There was no difference in a composite of clinical events (14.9% in the strict rate 
control group, 12.9% in the lenient group), NYHA class, or hospitalizations.[4] 
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RHYTHM CONTROL THERAPY IN ATRIAL FIBRILLATION: 
FIGURE5 – ALGORITHM FOR ACUTE RHYTM CONTROL IN AF : 
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FIGURE 6 – INITIATION OF LONG TERM RHYTHM CONTROL 
THERAPY TO IMPROVE SYMPTOMS OF AF:[4] 
 
CATHETER AND SURGICAL ABLATION FOR ATRIAL 
FIBRILLATION[3] 
Catheter ablation avoids antiarrhythmic drug toxicities but has procedural 
risks and requires an experienced center. For patients with previously untreated 
but recurrent paroxysmal AF, catheter ablation has similar efficacy to 
antiarrhythmic drug therapy and is superior to antiarrhythmic drugs for patients 
who have recurrent AF despite drug treatment. The procedure involves cardiac 
catheterization, transatrial septal puncture, and radiofrequency ablation or 
cryoablation to electrically isolate the regions around the pulmonary veins, 
abolishing the effect of triggering foci to interact with the left atrial AF substrate. 
Extensive areas of ablation are required, and gaps in healed ablation areas 
necessitate a repeat procedure in 20–50%of patients. Sinus rhythm is maintained 
for more than 1 year after one procedure in approximately 60% of patients and 
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in 70–80% of patients after multiple procedures. Some patients become more 
responsive to antiarrhythmic drugs. There is a 2–7% risk of major complications, 
including stroke (0.5–1%), cardiac tamponade (1%), phrenic nerve paralysis, 
bleeding from femoral access sites, and fluid overload with heart failure, that can 
emerge 1–3 days after the procedure. It is important to recognize the potential 
for delayed presentation of some complications. Ablation within the pulmonary 
veins can lead to pulmonary vein stenosis, presenting weeks to months after the 
procedure with dyspnea or hemoptysis. Esophageal ulcers can form immediately 
after the procedure and may rarely lead to a fistula between the left atrium and 
esophagus (estimated incidence of 0.1%) that presents as endocarditis and stroke 
10 days to 3 weeks after the procedure. 
Catheter ablation is less effective for persistent AF. More extensive 
ablation is often required, including areas that likely support reentry in regions 
outside the pulmonary venous antra, but individual strategies are debated. More 
than one ablation procedure is often required to maintain sinus rhythm. Surgical 
ablation of AF is typically performed concomitant with cardiac valve or coronary 
artery surgery and less commonly as a stand-alone procedure; however, for 
patients with persistent AF, surgical or hybrid procedures may have higher 
single-procedure efficacy. Risks include sinus node injury requiring pacemaker 
implantation. Surgical removal of the left atrial appendage may reduce stroke 
risk, although thrombus can form in the remnant of the appendage or if the 
appendage is not completely ligated. 
 
35 
 
SURGICAL APPROACHES TO ATRIAL FIBRILLATION 
The most effective surgical procedure for AF is the “cut-and sew” maze 
procedure developed by Cox in 1987. This operation involves multiple atrial 
incisions to isolate the PVs and to create lines of block in the left atrium and right 
atrium. In addition, the left and right atrial appendages are excised. In a study 
from a highly experienced surgical center in patients who underwent periodic 
24-hour Holter monitoring during follow-up, there was 83% freedom from AF 
off drugs at a median follow-up of 5.9 years after the most recent version of the 
cut-and-sew maze procedure (Cox maze III).However, because continuous 
monitoring for only 24 hours at a time often is insufficient to detect recurrent 
episodes of AF, the 83% long-term freedom from AF likely was an overestimate. 
The cut-and-sew Cox maze procedure has not been widely performed 
because it requires cardiopulmonary bypass, is technically difficult, and is 
associated with a mortality rate of 1% to 2%.A large variety of surgical ablation 
tools have been developed to simplify the Cox maze III procedure. These tools 
allow the surgeon to substitute an ablation line for a surgical incision. Some 
surgeons use a minimally invasive approach in which the ablation tools are 
inserted through small incisions between the ribs, and thoracoscopic video-
assisted epicardial ablation is performed. Several different types of energy have 
been used for surgical ablation: RF energy, cryoenergy, microwave, laser, and 
high-intensity focused ultrasound. The tool that most consistently produces 
transmural ablation lesions is a clamp device developed to isolate the PVs using 
bipolar RF energy. Various surgical ablation strategies have been used, including 
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PV isolation, left atrial ablation, and the Cox maze lesion set (Cox maze IV) in 
which a combination of RF and cryothermal ablation lines replace most of the 
surgical incisions. In a large series of patients with AF who underwent the Cox 
maze IV procedure, freedom from AF off antiarrthythmic drugs at 5 years was 
66%, with no difference in efficacy between patients with paroxysmal versus 
persistent AF or between patients with a stand-alone procedure versus a 
concomitant procedure. 
Surgical therapy for AF is appropriate as a concomitant procedure in 
patients with symptomatic AF undergoing open heart surgery for CAD or 
valvular disease. A stand-alone surgical procedure for AF is an option for 
patients who have not had a successful outcome from catheter ablation, who are 
not good candidates for catheter ablation, or who prefer a surgical approach over 
catheter ablation.[42,43] 
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MATERIALS AND METHODS 
STUDY CENTRE: Madras Medical College and Rajiv Gandhi Government 
General Hospital, Chennai -600003. 
STUDY DESIGN : Cross sectional study 
SAMPLE SIZE: 100 cases 
ETHICAL ISSUES:  
Approval from Institutional Ethics Committee was obtained before undertaking 
the study. Prior informed consent was taken from all the patients, 
INCLUSION CRITERIA: 
All patients aged more than 18 years , diagnosed with Atrial fibrillation , both 
clinically and confirmed by electrocardiogram. 
EXCLUSION CRITERIA: 
Patients less than 18 years were excluded from the study. 
Clinical grounds for inclusion: 
Age of the patients, sex, history of CAD, systemic hypertension, congenital heart 
disease, cardiomyopathies, thyroid disorder, COPD, cerebrovascular accidents 
were taken into account. The following features were noted: 
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1. Irregularly irregular pulse 
2. Pulse deficit > 10 calculated by simultaneous counting of pulse rate and 
heart rate by 2 observers. 
3. Absent ‘a’ wave in jugular venous pulsation. 
4. Variable intensity of first heart sound on auscultation. 
ECG Recording: 
12 lead ECG was taken for all the cases with a standardization of 1mV= 10 MM, 
with the paper speed at 25mm/sec. The following features were noted: 
1. Absence of P wave 
2. Atrial activity reflected by an irregularly corrugated deflection ‘f’ wave. 
3. Atrial rate >350/min 
4. Irregularly irregular RR interval 
In all patients who were included, a detailed history and physical examination 
was done.  
Other Investigations: 
1. Thyroid function tests 
2. Chest Xray PA view  
3. Blood glucose levels –fasting and post prandial 
4. PT/INR 
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5. Transthoracic echocardiography was done in all patients with attention to 
the following features: 
 Valvular / nonvalvular lesion 
 Valves involved 
 Left atrium size 
 Left atrial/ ventricular clot 
 Left atrial auto contrast 
 Ejection fraction 
 Left ventricular hypertrophy 
 Left ventricular diastolic dysfunction 
Patients were analysed with 2D echo, M mode  and colour Doppler. 
Paitents were grouped based on LA size enlargement according to 
American society of echocardiography. 
TABLE 5: LA SIZE SEVERITY 
LA SIZE MALES(cm) FEMALES(cm) 
NORMAL  <4.1 <3.9 
MILD  4.1-4.6 3.9-4.2 
MODERATE 4.7-5.1 4.3-4.6 
SEVERE >5.1 >4.6 
6. For patients who developed stroke as a complication of atrial fibrillation, 
CT scan of the brain was taken and the features were noted. 
The entire data was consolidated using Microsoft Excel 2013 and 
analysed. 
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OBSERVATION AND RESULTS 
 A total of 100 patients, all of whom had atrial fibrillation were included 
in the study. They were seen in different age groups ranging from 18 years to 81 
years, of which only a minority (4%) were aged less than 20 years. The mean 
age was 49 years. There was only a marginal difference between the other age 
groups, according to the present study. 
 
TABLE 6: PROPORTION OF CASES AMONG DIFFERENT AGE 
RANGES 
AGE_GROUP Frequency 
UP TO 20 YEARS 4 
21-40 YEARS 32 
41-60 YEARS 33 
61-80 YEARS 31 
Total 100 
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FIGURE 7 : AGE GROUP DISTRIBUTION 
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TABLE 7 : SEX WISE DISTRIBUTION 
GENDER Frequency Percent 
MALE 50 50.0 
FEMALE 50 50.0 
Total 100 100.0 
 
 
FIGURE 8 : GENDER DISTRIBUTION 
According to this study, males and females were affected equally. 
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TABLE 7 : SYMPTOM WISE DISTRIBUTION 
SYMPTOM FREQUENCY 
DYSPNEA 81 
PALPITATION  44 
FATIGUE 20 
CHEST PAIN  11 
SYNCOPE 2 
ASYMPTOMATIC 5 
 
FIGURE 9 : SYMPTOM DISTRIBUTION 
Dyspnea was the commonest symptom and was seen in 81%. The next 
common symptom was palpitation ,which was seen in 44% of the patients. 
Among the total of 100 cases, 5 were asymptomatic. 
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TABLE 8 : DISTRIBUTION OF DYSPNEA: 
NYHA  CLASS FREQUENCY PERCENTAGE 
I 16 19% 
II 34 42% 
III 22 27% 
IV 10 12% 
TOTAL 81 100% 
 
FIGURE 10 : DISTRIBUTION OF DYSPNEA ACCORDING TO NYHA 
CLASSIFICATION 
Among the patients who had presented with dyspnea, majority had 
dyspnea of class II (42% ) according to NYHA classification. 37% developed 
dyspnea of class III. 
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TABLE 9: SYMPTOM DISTRIBUTION ACCORDING TO MODIFIED 
EHRA SCORE: 
MODIFIED EHRA SCORE FREQUENCY 
1 10 
2a 22 
2b 11 
3 33 
4 24 
TOTAL 100 
 
FIGURE 11 : SYMPTOM DISTRIBUTION ACCORDING TO 
MODIFIED EHRA SCORE 
Modified EHRA score was used in the study to quantify the AF related 
symptoms, as recommended by the 2016 ESC guidelines for management of 
atrial fibrillation. Majority of the patients had a score of 3 (33%) followed by a 
score of 4(24%). 
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TABLE 10 :ETIOLOGY DISTRIBUTION: 
ETIOLOGY FREQUENCY 
RHD 45 
HYPERTENSION  20 
CAD 15 
OVERT 
HYPERTHYROIDISM 
7 
OVERT HYPOTHYROIDISM 3 
SUBCLINICAL 
HYPERTHYROIDISM 
2 
CAD & HYPERTENSION 2 
LONE AF 1 
COPD  1 
CTEPH 1 
DCM 2 
HCM 1 
TOTAL 100 
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FIGURE 12: DISTRIBUTION ACCORDING TO ETIOLOGY 
According to this study, the most common etiological factor that was 
associated with AF was Rheumatic Heart disease (45%). The next in line was 
hypertension (20%), closely followed by coronary artery disease (15%). The 
least common etiologies that were seen were cardiomyopathies, COPD, chronic 
pulmonary thromboembolic hypertension (CTEPH) and Lone AF, each of which 
contributed 1% of the total cases. 
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TABLE 11 : DISTRIBUTION ACCORDING TO HEART RATE: 
HEART RATE GROUP FREQUENCY 
<100 35 
100-140 53 
>140 12 
Total 100 
 
 
FIGURE 13: DISTRIBUTION ACCORDING TO HEART RATE 
At presentation, majority had a heart rate between 100-140 (53%). Only 
12% belonged to the heart rate group  of less than 100. 
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TABLE 12 : COMPLICATION: 
COMPLICATION FREQUENCY 
HEART FAILURE 32 
THROMBOEMBOLISM 20 
 
 
FIGURE 14: DISTRIBUTION ACCORDING TO COMPLICATIONS 
 The most common complication associated with atrial fibrillation in the 
present study was heart failure, seen in 32% of the patients. This was followed 
by thromboembolism(20%) 
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TABLE 13 : SEX DISTRIBUTION OF HEART FAILURE : 
HEART FAILURE FREQUENCY PERCENTAGE 
MALES 15 46% 
FEMALES 17 54% 
TOTAL 32 100% 
 
 
FIGURE 15: SEX DISTRIBUTION OF HEART FAILURE 
 Among the patients who developed heart failure , 54% were males and 
46% were females. 
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Table 14 :ETIOLOGY DISTRIBUTION OF HEART FAILURE: 
ETIOLOGY FREQUENCY PERCENTAGE 
RHD 14 44% 
CAD 12 38% 
HYPERTENSION 3 9% 
DCM 1 3% 
COPD 1 3% 
HYPOTHYROIDISM 1 3% 
TOTAL 32 100% 
 Rheumatic heart disease contributed to the majority of heart failure cases 
( 44%) followed by coronary artery disease (38%). 
 
FIGURE 16 : ETIOLOGY DISTRIBUTION OF HEART FAILURE 
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TABLE 15 : PATTERN OF THROMBOEMBOLISM: 
THROMBOEMBOLISM FREQUENCY PERCENTAGE 
CVA 14 70% 
PERIPHERAL EMBOLISM 6 30% 
TOTAL 20 100% 
 
 
FIGURE 17 : PATTERN OF THROMBOEMBOLISM 
 Among the 20 patients who developed thromboembolism, 70% were 
due to CVA and the remaining 30% as a result of peripheral embolism. 
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TABLE 16: SEX DISTRIBUTION OF THROMBOEMBOLISM: 
  MALES FEMALES TOTAL 
CVA 7 7 14 
PERIPHERAL 
EMBOLISM 0 6 6 
 
 
FIGURE 18 : SEX DISTRIBUTION OF THROMBOEMBOLISM 
 Among the 20 patients who developed thromboembolism, CVA was 
seen to have developed in an equal proportion in both males and females. On 
the contrary all the 6 patients who developed peripheral embolism were 
females. 
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TABLE 17 : ETIOLOGY DISTRIBUTION OF CVA: 
ETIOLOGY FREQUENCY PERCENTAGE 
CAD 6 43% 
RHD 4 29% 
HYPERTENSION 3 21% 
DCM 1 7% 
TOTAL 14 100% 
 
FIGURE 19 : ETIOLOGY DISTRIBUTION OF CVA 
ETIOLOGY DISTRIBUTION OF PERIPHERAL EMBOLISM: 
 All the 6 patients who developed peripheral embolism were associated 
with rheumatic heart disease. 
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TABLE 18 : CHA2DS2VASC SCORE AMONG NON VALVULAR AF: 
CHA2DS2VASc Frequency Percentage 
0 13 23% 
1 6 11% 
2 11 20% 
3 12 22% 
4 6 11% 
5 6 11% 
6 1 2% 
Total 55 100% 
 
FIGURE 20: CHA2DS2VASc SCORE AMONG NON VALVULAR AF: 
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TABLE 19 :BLEEDING DUE TO ANTICOAGULATION 
BLEEDING MANIFESTATION FREQUENCY PERCENT 
INTRACEREBRAL HEMORRHAGE 3 33.3% 
ECCHYMOSES  1 11.1% 
EPISTAXIS 1 11.1% 
GUM BLEED 1 11.1% 
HEMATEMESIS 1 11.1% 
CEREBELLAR HEMORRHAGE 1 11.1% 
SUBDURAL HEMATOMA 1 11.1% 
Total 9 100.0% 
 
 
FIGURE 21: COMPLICATIONS DUE TO BLEEDING 
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Among the total number of 100 cases, 87 were anticoagulated ,of which 
9 patients developed bleeding manifestations and illustrated above due to 
anticoagulation. 33.3 % of them suffered from intracerebral hemorrhage. 
ECHOCARDIOGRAPHIC PARAMETERS: 
TABLE 20 : VALVE LESION DISTRIBUTION AMONG RHD : 
RHD Frequency Percent 
MS 23 51% 
MS.MR 13 30% 
MS,AS,AR 6 13% 
MS,MR,AS,AR 1 2% 
S/P MVR 2 4% 
TOTAL 45 100% 
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FIGURE 22 : VALVE LESION DISTRIBUTION AMONG RHD 
 
 Among the 45% of patients, mitral stenosis was the predominant valvular 
lesion (51%) , followed by MS with MR( 30%). Aortic valve component was 
seen in 15% of the cases. 2 % were those who had undergone a mitral valve 
replacement. 
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TABLE 21 :PERCENTAGE OF LA AUTOCONTRAST: 
LA AUTOCONTRAST FREQUENCY 
NO 87 
YES 13 
Total 100 
 
FIGURE 23 : PERCENTAGE OF LA AUTO CONTRAST 
 13% of the cases had a spontaneous echo contrast , whereas 87% did 
not. 
LA AUTOCONTRAST AND CVA: 
 CVA was associated with 31% of those who had an LA auto contrast, 
while 11% of the patients with CVA did not have a spontaneous echo contrast. 
LA AUTOCONTRAST AND PERIPHERAL EMBOLISM : 
Among the patients who developed Peripheral embolism (6%) , none 
had a spontaneous echo contrast. 
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TABLE 22 : PERCENTAGE OF CLOT ON ECHO: 
CLOT Frequency 
NO CLOT 85 
LA CLOT 11 
LV CLOT 3 
PROSTHETIC  VALVE 
THROMBOSIS 
1 
Total 100 
 
 
FIGURE 24 : PERCENTAGE OF CLOT ON ECHO 
 85% of the patients included in the study did not have a clot on 
transthoracic echocardiogram. The commonest clot that was observed was LA 
clot (11%) followed by LV clot(3%) and prosthetic valve thrombosis(1%). 
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TABLE 23 : HEART RATE AND CLOT ON ECHO : 
 HR_RATE_GROUP Total 
<100 100-
140 
>140 
CLOT 
LA 
CLOT 
Count 1 8 2 11 
% within 
HR_RATE_GROUP 
2.9% 15.1% 16.7% 11.0% 
LV 
CLOT 
Count 2 0 1 3 
% within 
HR_RATE_GROUP 
5.7% 0.0% 8.3% 3.0% 
PR V 
CLOT 
Count 0 0 1 1 
% within 
HR_RATE_GROUP 
0.0% 0.0% 8.3% 1.0% 
Total 
Count 35 53 12 100 
% within 
HR_RATE_GROUP 
100.0% 100.0% 100.0% 100.0% 
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FIGURE 25: CLOT ON ECHO AND HEART RATE 
 33% of the patients who had a clot on echo, had presented with a rapid 
heart rate of  more than 140/minute. Heart rate ranging between 100-140/min 
were associated with 15% of the patients with clot , whereas 9% with a heart rate 
less than 100/min had clot on echo. 
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TABLE 24 :CLOT ON ECHO AND CVA: 
 CLOT Total 
LA 
CLOT 
LV 
CLOT 
NO 
CLOT 
PR V 
CLOT 
CVA 
N 
Count 7 0 78 1 86 
% within 
CLOT 
63.6% 0.0% 91.7% 100.0% 86.0% 
Y 
Count 4 3 7 0 14 
% within 
CLOT 
36.4% 100.0% 82.3% 0.0% 14.0% 
Total 
Count 11 3 85 1 100 
% within 
CLOT 
100.0% 100.0% 100.0% 100.0% 100.0% 
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FIGURE26 : CLOT ON ECHO AND CVA 
            Among the 14 patients who developed CVA,7 patients had a clot on echo 
,of which 4 had an LA clot and 3 patients had LV clot. The remaining 7 patients 
did not have a clot on echo. 
Among the 15 patients who had a clot on echo,7 patients developed CVA 
whereas CVA was not observed in 8 patients. 
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TABLE 25 : CLOT ON ECHO AND PERIPHERAL EMBOLISM: 
 CLOT Total 
LA 
CLOT 
LV 
CLOT 
NO 
CLOT 
PR V 
CLOT 
PVD 
N 
Count 6 3 84 1 94 
% within 
CLOT 
54.5% 100.0% 98.8% 100.0% 94.0% 
Y 
Count 5 0 1 0 6 
% within 
CLOT 
45.5% 0.0% 1.2% 0.0% 6.0% 
Total 
Count 11 3 85 1 100 
% within 
CLOT 
100.0% 100.0% 100.0% 100.0% 100.0% 
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FIGURE 27 : CLOT ON ECHO AND PERIPHERAL EMBOLISM 
 Among the 6 patients who developed Peripheral embolism, 5 had LA clot 
and 1 patient had no clot on echo. 
  
54.50%
100.00% 98.80% 100.00%
46%
0% 1% 0%
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
120.00%
LA CLOT LV CLOT NO CLOT PR V CLOT
N Y
67 
 
TABLE 26: DISTRIBUTION OF SEVERITY OF LV SYSTOLIC 
DYSFUNCTION 
LVSD FREQUENCY 
NORMAL 85 
MILD 5 
MODERATE 4 
SEVERE 11 
Total 100 
 
 
FIGURE28 : DISTRIBUTION OF LVSD 
 Out of the 100 patients, LVSD was seen in 19 patients , of which 11 had 
severe LVSD with an ejection fraction of 30%. 
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TABLE 27 : LEFT VENTRICULAR HYPERTROPHY  
LVH FREQUENCY 
No 72 
Yes 28 
 Total 100 
 
 
 FIGURE 29 : PERCENTAGE OF LVH 
 Left ventricular hypertrophy was seen in 28% of the patients. 
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LA SIZE : 
1. TABLE 28 :AGE DISTRIBUTION IN MALES: 
 
 LA_size_male(cm) Total 
<4.1   4.1-4.6                       4.7-5.1                 >5.1                
AGE_GR
OUP 
UP TO 20 
YEARS 
Count 1 1 0 0 2 
%   11.1% 10.0% 0.0% 0.0% 4.0% 
21-40 
YEARS 
Count 5 0 2 4 11 
%   55.6% 0.0% 10.5% 33.3% 22.0% 
41-60 
YEARS 
Count 1 3 9 4 17 
%   11.1% 30.0% 47.4% 33.3% 34.0% 
61-80 
YEARS 
Count 2 6 8 4 20 
%   22.2% 60.0% 42.1% 33.3% 40.0% 
Total 
Count 9 10 19 12 50 
%   100.0% 100.0% 100.0% 100.0% 100.0% 
 
FIGURE 30– LA SIZE  AND AGE DISTRIBUTION IN MALES 
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2. TABLE 29: AGE DISTRIBUTION IN FEMALES 
 LA_size_Female(cm) Total 
<3.9    3.9-4.2    4.3-4.6  >4.6 
Age_ 
Group 
Up To 
20 Years 
Count 1 0 0 1 2 
%   16.7% 0.0% 0.0% 2.9% 4.0% 
21-40 
Years 
Count 5 3 2 11 21 
%   83.3% 75.0% 40.0% 31.4% 42.0% 
41-60 
Years 
Count 0 1 2 13 16 
%   0.0% 25.0% 40.0% 37.1% 32.0% 
61-80 
Years 
Count 0 0 1 10 11 
%   0.0% 0.0% 20.0% 28.6% 22.0% 
Total 
Count 6 4 5 35 50 
%   100.0% 100.0% 100.0% 100.0% 100.0% 
 
FIGURE 31: LA SIZE AGE DISTRIBUTION IN FEMALES 
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3. TABLE 30  : LA SIZE AND VALVULAR HEART DISEASE: 
 
 LA_size_male(cm) Total 
4.1-4.6 4.7-5.1 >5.1 
Lesion 
MS 
Count 1 5 1 7 
% 50.0% 50.0% 14.3% 36.8% 
MS, AS, 
AR 
Count 1 4 1 6 
% 50.0% 40.0% 14.3% 31.6% 
MS,MR 
Count 0 0 5 5 
% 0.0% 0.0% 71.4% 26.3% 
MS,MR, 
AS,AR 
Count 0 1 0 1 
% 0.0% 10.0% 0.0% 5.3% 
Total 
Count 2 10 7 19 
% 100.0% 100.0% 100.0% 100.0% 
 
FIGURE 32: LA SIZE AND VALVULAR HEART DISEASE IN MALES 
72% of patients with severe LA enlargement in males had MS, MR where 
as 14% had MS alone 14% had MS,AS,AR 
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4. TABLE 31 : LA SIZE AND VALVULAR HEART DISEASE IN 
FEMALES 
 
 LA_size_Female(cm) Total 
3.9-4.2 4.3-4.6 >4.6 
Lesion 
MS 
Count 2 2 10 14 
% 100.0% 66.7% 55.6% 60.9% 
MS, 
MR 
Count 0 1 7 8 
% 0.0% 33.3% 38.9% 34.8% 
S/P 
MVR 
Count 0 0 1 1 
% 0.0% 0.0% 5.6% 4.3% 
Total 
Count 2 3 18 23 
% 100.0% 100.0% 100.0% 100.0% 
 
FIGURE 33:  LA SIZE AND VALVULAR HEART DISEASE IN 
FEMALES 
56% of females who had severe LA enlargement had pure MS while, 39% 
had MS, MR. 
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5. TABLE 32 : LA SIZE AND CLOT ON ECHO IN MALES : 
 
 LA_size male(cm) Total 
<4.1 4.1-4.6 4.7-5.1 >5.1 
Clot 
LA Clot 
Count 0 0 2 1 3 
% 0.0% 0.0% 10.5% 8.3% 6.0% 
LV Clot 
Count 1 0 0 0 1 
% 11.1% 0.0% 0.0% 0.0% 2.0% 
Total  1 0 2 1 4 
 
 
FIGURE 34 : LA SIZE AND CLOT ON ECHO IN MALES 
All male patients who had LA clot were having LA enlargement. 
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6. TABLE 33 : LA SIZE AND CLOT ON ECHO IN FEMALES 
 
 LA_size_Female(cm) Total 
<3.9 3.9-4.2 4.3-4.6  >4.6 
CLOT 
LA CLOT 
Count 0 0 0 8 8 
% 0.0% 0.0% 0.0% 22.9% 16.0% 
LV CLOT 
Count 0 0 0 2 2 
% 0.0% 0.0% 0.0% 5.7% 4.0% 
PR V 
CLOT 
Count 0 0 0 1 1 
% 0.0% 0.0% 0.0% 2.9% 2.0% 
Total Count 0 0 0 11 11 
 
 
FIGURE35 : LA SIZE AND CLOT ON ECHO IN FEMALES 
All female patients who had clot on echo were seen to have severe LA 
enlargement. 
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7. TABLE 34: LA SIZE AND CVA IN MALES: 
 
 LA_size_male Total 
<4.1 4.1-4.6 4.7-5.1 >5.1 
CVA 
N 
Count 8 10 16 9 43 
% 88.9% 100.0% 84.2% 75.0% 86.0% 
Y 
Count 1 0 3 3 7 
% 11.1% 0.0% 15.8% 25.0% 14.0% 
Total 
Count 9 10 19 12 50 
% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
 
 
FIGURE 36 : LA SIZE AND CVA IN MALES 
Among the male patients with LA enlargement, 25% with severe LA 
enlargement had CVAand 16% with moderate LA enlargement had CVA. 
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8. TABLE 35: LA SIZE AND CVA IN FEMALES: 
 
 LA_size_male_Female Total 
<3.9 3.9-4.2 4.3-4.6 >4.6 
CVA 
N 
Count 6 4 3 25 38 
% 100.0% 100.0% 60.0% 71.4% 76.0% 
Y 
Count 0 0 2 10 12 
% 0.0% 0.0% 40.0% 28.6% 24.0% 
Total 
Count 6 4 5 35 50 
% 100.0% 100.0% 100.0% 100.0% 100.0% 
       
 
FIGURE 37– LA SIZE AND CVA IN FEMALES 
 Among the female patients with LA enlargement, 29% with severe 
enlargement had CVA and 40% with moderate enlargement had CVA.  
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DISCUSSION 
 The present study was undertaken to analyse the etiological, clinical and 
echocardiographic profile of atrial fibrillation and its complications. 
AGE: 
The mean age of AF in the present study was 49 years. Benjamin.O et 
al[44] reported mean age as 58 in their study. AFFIRM study[45] has reported mean 
age as 70 years. The mean age is higher in their studies as most of the population 
was above 50 years of age in their study group, which differed from the present 
study. 
SEX: 
Males and females were seen to be affected equally in our study. 
According to AFFIRM study, incidence in males was 61% Framingham heart 
study[46] reported a higher incidence in males. 
ETIOLOGY: 
RHD: 
In our study out of 100 cases, 45 had rheumatic heart disease as the 
etiology. Bernard L.J et al47] concluded in their study that 70% of their population 
had RHD as the etiology. AFFIRM study reports very low incidence of RHD in 
their study. Studies that were done in tropical countries all concur with a higher 
incidence of atrial fibrillation in RHD as compared to the Western population. 
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HYPERTENSION: 
The next common cause of AF in our study was hypertension seen in 20% of the 
cases. According to the Framingham study[46]  , half of the cases were accounted 
by hypertension. In the AFFIRM study[45] , hypertension was present in 71%. 
The association with hypertension is lesser in our study than the above trials. 
CORONARY ARTERY DISEASE: 
CAD was present in 15% of the cases in our study. In the AFFIRM45] study, CAD 
was present in 38% of the cases. Sameul Levy [48] et al reported 16.6% of CAD 
as the underlying cause 
OTHER ETIOLOGIES: 
Thyroid dysfunction was seen in 12 cases of which 7 had overt 
hyperthyroidism, 2 had subclinical hyperthyroidism and 3 had overt 
hypothyroidism.  Auer J et al[49]  reported that AF occurred in 13.8% with overt 
hyperthyroidism and 12.7% were seen with subclinical hyperthyroidism. 
Barbisan et al[50]  in their study noted that out of 72 patients with atrial fibrillation, 
16.6% had thyroid dysfunction out of which 5.6% had hypothyroidism. 
SYMPTOM ANALYSIS: 
Dyspnea was the most common symptom seen in 81% of the patients 
followed by palpitation in 44%. Dyspnea was reported by Tischer et al[51] in 62% 
of patients and palpitation in 33%. Flaker et al[52] noted that 78% had dyspnea 
and 11% had chest pain. 
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COMPLICATIONS: 
Heart failure was seen in 32% of patients and thromboembolism was seen 
in 20% in our study. AFFIRM[45] trial suggests that 32% of their patients had left 
ventricular dysfunction. 14 patients in our study had cerebral embolism and 6 
had peripheral embolism. CVA was predominant in Coronary artery disease 
(43% of CVA was due to CAD) with a higher CHA2DS2Vasc score, while 
peripheral embolism was predominant in females of rheumatic heart disease 
patients in our study. 
Bleeding manifestations as a complication of anticoagulation was noted 
in 9% of the cases in our study. All of them had an INR>4. 
ECHOCARDIOGRAPHIC FEATURES: 
VALVE LESION:  
Among the 45% of patients, mitral stenosis was the predominant valvular 
lesion (51%) , followed by MS with MR( 30%). Aortic valve component was 
seen in 15% of the cases. SK Sharma et al observed in their study that Pure mitral 
stenosis was seen 48% of cases . Predominant mitral regurgitation 35% of cases. 
The AFFIRM Investigators found that mitral regurgitation was present in 15% 
of their cases. 
LA AUTO CONTRAST: 
13 patients with AF had spontaneous echo contrast of which 4 were 
associated with CVA  in our study. 
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CLOT on ECHOCARDIOGRAPHY: 
11 patients had an LA clot, 3 had LV clot and 1 patient had prosthetic 
valve thrombosis. 87% did not have clot on echo. 33% of the patients who had a 
clot on echo, had presented with a rapid heart rate of  more than 140/minute. 
CLOT ON ECHO AND CVA:  
Among the 14 patients who developed CVA while 7 patients ,4 had an 
LA clot and 3 patients had LVclot. The remaining 7 patients did not have a clot 
on echo. Among the 15 patients who had a clot on echo,7 patients developed 
CVA whereas CVA was not observed in 8 patients. Among the 6 patients who 
developed PVD, 5 had LA clot and 1 patient had no clot on echo. Studies by 
Wood e t al and Deverall P et al observed that systemic embolization occurs 
primarily in the presence of atrial fibrillation. 
 LA SIZE : 
72% of patients with severe LA enlargement in males had MS, MR where 
as 14% had MS alone 14% had MS,AS,AR.56% of females who had severe LA 
enlargement had pure MS while, 39% had MS,MR. 
All male patients who had LA clot were having LA enlargement. All 
female patients who had clot on echo were seen to have severe LA enlargement. 
.Mahmood ul Hassan et al[57] noted in their study that the frequency of left atrial 
and appendage clots on trans-oesophageal echocardiography in patients with 
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severe mitral stenosis is common and more frequent in patients with AF and LA 
size > or = 45 mm. 
Among the male patients with LA enlargement, 25% with severe LA 
enlargement had CVA and 16% with moderate LA enlargement had 
CVA.Among the female patients with LA enlargement, 29% with severe 
enlargement had CVA and 40% with moderate enlargement had CVA. JieXue et 
al[56] noted in their study of 313 patients that LA size is an independent predictor 
of total recurrent ischemic stroke and the composite of recurrent cardioembolic 
or cryptogenic stroke. 
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION: 
LVSD was seen in 19 patients , out of which 58% had severe LVSD with 
ejection fraction of 30%. AFFIRM[45] trial suggests that 32% of their patients had 
left ventricular dysfunction. LV systolic dysfunction (ejection fraction <50%) 
occurred in 25% of cases noted by Teicholz et al[55]  
LEFT VENTRICULAR HYPERTROPHY: 
Left ventricular hypertrophy was seen in 28% of the patients.Teicholz et al[55]   
observed that LAE and LVH with normal EF are commoner in hypertensive pts 
with suggesting diastolic dysfunction. 
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CONCLUSION 
According to this study, 
1. The mean age of atrial fibrillation was 49 years,males and females being 
equally affected. 
2. Dyspnea was the most common presenting symptom followed by 
palpitation, 
3. RHD was the most common etiological factor followed by hypertension 
and CAD. 
4. Predominant valve affected is the mitral valve both in isolation and in 
combination.  
5. Heart failure was the most common complication followed by 
thromboembolism 
6. Stroke was more common than peripheral embolism 
7. Females of rheumatic heart disease had the highest frequency of 
peripheral embolism. 
8. The presence of clot on echo increases the risk of thromboembolism 
9. Higher heart rate > 140/min is a risk factor for clot formation. 
10. LA enlargement had a higher incidence of clot on echocardiography 
11. LA enlargement had a higher incidence of ischemic stroke. 
Meticulous evaluation of risk factors and prompt treatment will reduce 
the complications, morbidity and mortality. 
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LIMITATIONS 
1. Sample size was small due to time constraint 
2. The study was conducted in patients admitted at a single tertiary care 
center.  
3. This was a cross sectional study and follow up details were not 
evaluated. 
4. Transesophageal echo was not done for better detection of clot. 
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ANNEXURES 
PROFORMA 
Clinical and Echocardiographic profile of Atrial Fibrillation 
Name : 
Age/Sex : 
OP/IP No : 
Occupation : 
Address : 
Contact No. : 
SYMPTOMS 
◊ Palpitations  
◊ Dyspnea 
◊ Chest pain 
◊ Syncope 
◊ Cough 
◊ Hemoptysis 
◊ Leg swelling 
◊ Weakness of limbs 
◊ Bleeding manifestaions 
◊ Dysphagia  
 
Patient Characteristics 
◊ Smoker 
◊ Alcoholic 
◊ Diabetic 
◊ Hypertensive 
◊ Coronary Artery Disease 
◊ Stroke  
◊ Bronchial Asthma/COPD 
◊ Thyroid disorder 
◊ H/o cardiac surgery 
 
GENERAL EXAMINATION : 
 
VITALS : 
SYSTEMIC EXAMINATION 
CVS: 
 
RS: 
P/A 
CNS: 
INVESTIGATIONS: 
TFT 
PT/INR 
ECG 
Chest XRAY 
ECHO 
 
Others : 
 
DIAGNOSIS: 
INFORMATION SHEET 
We are conducting a study on “Clinical and Echocardiographic 
profile of Atrial Fibrillation” among patients attending Rajiv Gandhi 
Government General Hospital, Chennai and for that your specimen may be 
valuable to us. 
The purpose of this study is to analyse the clinical, echocardiographic 
profile of Atrial fibrillation cases in medical  ward and OPD. We are selecting 
certain cases and if you are found eligible, we may perform extra tests and 
special studies which in any way do not affect your final report or management. 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment. 
 
Signature of Investigator Signature of Participant
Date : 
Place : 
PATIENT CONSENT FORM 
Study Detail : Clinical and Echocardiographic profile of Atrial 
Fibrillation 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I have 
the opportunity to ask question and all my questions and doubts have been answered 
to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to 
look at my health records, both in respect of current study and any further research 
that may be conducted in relation to it, even if I withdraw from the study I agree to 
this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study. 
I agree to take part in the above study and to comply with the instructions given during 
the study and faithfully cooperate with the study team and to immediately inform 
the study staff if I suffer from any deterioration in my health or well being or any 
unexpected or unusual symptoms. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and diagnostic tests 
including hematological, biochemical, radiological tests. 
 
 
 
 
Signature/thumb impression  
Patient’s Name and Address    
 
 
 
  
Signature of Investigator 
Dr.G. AISHWARYA. 
  
PLAGIARISM DIGITAL RECEIPT 
 
 
  
PLAGIARISM SCREENSHOT  
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